By SPC News Staff
The FDA approved romosozumab-aqqg (Evenity, Amgen/UCB) to treat osteoporosis in postmenopausal women with a high-fracture risk: women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.
Romosozumab-aqqg is a monoclonal antibody that blocks the effects of the protein sclerostin and works mainly by increasing new bone formation. It is the first and only bone builder with a unique